摘要
目的对比研究洛铂灌注与顺铂灌注治疗恶性腹腔积液的疗效及安全性差异，总结最合理的治疗方案，促进预后。方法随机抽取58例恶性腹腔积液病例资料，根据灌注药物不同分成洛铂组30例和顺铂组28例，其中洛铂30mg／m^2，顺铂60mg／m^2，治疗结束后评价近期疗效、生活质量评分及毒副反应情况。结果两组生活质量评分及近期疗效比较差异无统计学意义（P〉0．05）。洛铂组毒性反应发生率低于顺铂组（20．0％比28．6％），差异有统计学意义（P〈0．05）。结论①无论是洛铂灌注抑或顺铂灌注，二者均能较好的控制恶性腹腔积液，总体疗效相当；②从药物安全性角度上评估，洛铂腹腔内灌注安全性更引人瞩目，毒副反应更少。
Objective To compare the efficacy and safety of intraperitoneal perfusion of lobaplatin and cisplatin in the treatment of malignant ascites, and summarize the reasonable treatment plan to improve the prognosis. Methods We chose 58 patients with malignant ascites in our hospital. All the patients were divided into two groups according to the infusion drug, and treated with lobaplatin 30 mg/m^2 and cisplatin 60 mg/m^2 respectively. Then we evaluated the curative effect, life quality score, and the toxicity of two groups. Results There were no statistically significant differences in the life quality score and short-term efficacy between two groups （P〉0.05）. The incidence of toxic reaction was 20.0% in lobaplatin group and 28.6% in cisplatin group, with statistically significant difference （P〈0.05）. Conclusions （1） Both lobaplatin and cisplatin infusion can control malignant ascites well, with equivalent overall curative effect; （2） from the point of view of drug safety, intraperitoneal infusion of loboplatin is more safe, with less toxic side effects.
出处
《国际医药卫生导报》
2017年第6期867-869,共3页
International Medicine and Health Guidance News
关键词
洛铂
顺铂
恶性腹腔积液
灌注治疗
疗效
Lobaplatin
Cisplatin
Malignant ascites
Perfusion therapy
Curative effect
